Welcome to our dedicated page for Rogers news (Ticker: ROG), a resource for investors and traders seeking the latest updates and insights on Rogers stock.
Rogers Corporation reports developments tied to its engineered materials business, including advanced electronic materials and elastomeric materials sold for EV/HEV, automotive safety and radar systems, mobile devices, renewable energy, wireless infrastructure, energy-efficient motor drives, industrial equipment and related applications. The company manufactures in the United States, Asia and Europe and serves original equipment manufacturers and component suppliers.
Recurring Rogers news includes quarterly and annual financial results, end-market demand across industrial, electronics and communications, and automotive markets, profitability and cost-improvement initiatives, product-development commentary, capital-structure disclosures, and board or executive governance updates.
Genentech, part of the Roche Group, announced publication of Evrysdi™ (risdiplam) data from the pivotal FIREFISH study. The study showed that 90% of infants with symptomatic Type 1 spinal muscular atrophy (SMA) survived without permanent ventilation after 12 months of treatment. Additionally, 33% of infants could sit independently for at least 5 seconds. The data highlights the drug's effectiveness in increasing survival of motor neuron (SMN) protein levels. Evrysdi, FDA-approved in August 2020, has promising implications for treating SMA in infants.
Rogers Corporation (NYSE:ROG) reported Q4 2020 net sales of $210.7 million, marking a 4% increase from Q3 and a 21% rise year-on-year. Gross margin improved to 38.3%, driven by operational efficiencies despite rising costs. For the full year, net sales totaled $802.6 million, a decline of 11% due to pandemic-related challenges. GAAP earnings per diluted share were $0.81 in Q4, up from $0.37 in Q3, while full-year earnings rose to $2.67. The company anticipates Q1 2021 net sales between $215-$225 million, amidst recovery from a facility fire in South Korea.
Rogers Corporation (NYSE: ROG) announced the retirement of CFO Michael M. Ludwig, who will remain until a successor is appointed. The company praised his leadership in enhancing profitability and cash flow. Rogers specializes in engineered materials across sectors like advanced mobility and connectivity, operating globally with multiple manufacturing facilities. The company highlights risks in forward-looking statements related to management retention and employee costs, indicating potential uncertainties ahead.
Genentech has announced positive results from four Phase III studies on its investigational bispecific antibody, faricimab, targeting diabetic macular edema (DME) and wet age-related macular degeneration (nAMD). Faricimab demonstrated non-inferior vision gains compared to aflibercept, with patients able to extend treatment intervals up to four months. Approximately 52.8% of DME patients and 45.7% of nAMD patients achieved four-month dosing in the first year. The studies showed no unexpected safety signals, indicating faricimab may improve treatment adherence and outcomes.
On February 9, 2021, a fire occurred at Rogers Corporation's (NYSE:ROG) UTIS manufacturing facility in Ansan, South Korea. The site was evacuated without injuries, but the facility suffered extensive damage. The fire's cause is under investigation. This site produces eSorba® polyurethane foams, crucial for portable electronics, and will see operational disruptions, though the duration is yet unknown. The UTIS business accounts for less than 4% of Rogers' annual sales and employs about 50 people.
Rogers Corporation (NYSE:ROG) is set to announce its fourth quarter and full year 2020 results on February 18, following market close. This will be accompanied by a conference call at 5:00 pm ET, featuring key executives including President and CEO Bruce Hoechner. Investors can access the live webcast and presentation on Rogers' investor website. The company, with over 180 years of materials science experience, specializes in engineered materials for advanced connectivity, mobility applications, and more, operating globally across multiple countries.
Genentech announced positive topline results from two Phase III studies, TENAYA and LUCERNE, for its bispecific antibody faricimab in treating neovascular age-related macular degeneration (nAMD). Both studies met their primary endpoint, demonstrating that faricimab injections at intervals up to 16 weeks achieved comparable visual acuity to aflibercept given every 8 weeks. Approximately 45% of participants receiving faricimab were treated every 16 weeks, marking a significant milestone in treatment durability. Faricimab was generally well tolerated with no new safety concerns.
Genentech, part of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the FDA has accepted its supplemental New Drug Application (sNDA) for Esbriet® (pirfenidone) to treat unclassifiable interstitial lung disease (UILD) and granted Priority Review. A decision is expected by May 2021. This sNDA is based on a Phase II trial, the first randomized controlled study for UILD, indicating Esbriet may benefit patients. The treatment has previously received Orphan Drug and Breakthrough Therapy Designations from the FDA.
Genentech has received Breakthrough Therapy Designation (BTD) from the FDA for tiragolumab, an innovative cancer immunotherapy targeting TIGIT, in combination with Tecentriq for treating metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. This marks the first anti-TIGIT molecule to receive BTD, based on promising results from the Phase II CITYSCAPE trial, which demonstrated improved overall response rates and progression-free survival. Genentech plans to further develop tiragolumab across multiple cancer types, aiming for significant advancements in treatment.
Genentech has received FDA approval for a shorter two-hour infusion time for Ocrevus (ocrelizumab) for patients with relapsing or primary progressive multiple sclerosis (MS) without prior serious infusion reactions. This decision follows data from the ENSEMBLE PLUS study, showing comparable infusion reaction rates between the two-hour and previous 3.5-hour infusions. Ocrevus is already the most prescribed MS medication in the U.S., with dosing every six months and approved in 94 countries.